|Former: Atención Farmacéutica|
|Journal edited by Rasgo Editorial since 1983|
Manuela Velázquez Prieto
EDITOR IN CHIEF
Jaime E. Poquet Jornet
Tomás Casasín Edo
Virginia Hernández Corredoira
Ramón Jódar Masanés
Juan Carlos Juárez Giménez
Volume 19 - Issue 3, May-June 2017
OFF-LABEL USE OF CANNABINOIDS: EFFICACY AND SAFETY
SÁNCHEZ GUNDÍN JULIA, VALERA RUBIO MARTA, GÓMEZ ROMERO LOURDES, GÓMEZ MORENO ISABEL, FLOR GARCÍA AMPARO, BARREDA HERNÁNDEZ DOLORES
Objective: To assess the tolerability, efficacy and safety of delta-9-tetrahydrocan-nabinol (THC)-cannabidiol (CBD) for the treatment of spasticity, painful spasms and/or neuropathic pain not secondary to multiple sclerosis (MS).
Method: A retrospective, descriptive study (02/2012-02/2016) of patients with spasticity, painful spasms and/or neuropathic pain not secondary to MS and treated with THC-CBD.
Variables collected: gender, age, drug therapy prior to THC-CBD, optimal daily dose and concomitant treatment with THC-CBD. Spasticity was assessed by ASHWORTH scale before and after initiation of cannabinoid, and safety by the emergence of adverse drug reactions. We also collected the length of treatment.
Results: Nine patients (62% males, mean age 45 years). Most common diagnosisis was spastic paraplegia related to other diseases (89%) mean of prescribed drugs prior to THC-CBD: 2, most common were: botulinum toxin (78%) baclofen (66%) and tizanidine (44%) mean number of THC-CBD daily sprays: 6.44% of
the treated patients were not prescribed with any other concomitant drug, and the remaining had a mean of two drugs, in addition to THC-CBD.
ASHWORTH scale: three-points at initial treatment, improving to two points following treatment.
Safety: 67% patients experienced adverse reactions leading to the drug with drawal in only one patient (intercurrent digestive infectious process). The most common was somnolence. At the end of the study, 67% patients remained on treatment with THC-CBD after a median of 25 months (543) and experienced no loss of efficacy.
Conclusions: THC-CBD could be a treatment option for spasticity, painful spasms and/or neuropathic pain in patients not diagnosed with MS, who have not responded adequately to other conventional anti-spasticity therapies, being a safe and effective treatment choice.
EFFICACY - ENDOCANNABINOIDS - SAFETY - SPASTICITY